GLP-1 Claims Nearly Triple at South Africa's Largest Insurer as Cost Becomes the Barrier

What Happened

The number of members claiming for GLP-1 weight-loss medicines through Discovery, which administers South Africa's largest private health plan, almost tripled to 61,200 members in the three years through 2025 — even as those members claimed for the drugs for an average of just 5.4 months.

The plan provides no dedicated chronic-medicine benefit for the medicines when they are prescribed specifically for obesity, so patients draw on day-to-day benefits, including medical savings, or pay out of pocket. Discovery cautions that claims data do not necessarily reflect how long patients remain on treatment, and says it cannot determine how many members stop claiming because of cost.

"Cost is therefore an important barrier, particularly where treatment is paid for out of pocket," said Mosima Mabunda, chief clinical officer of Discovery Vitality, the insurer's wellness-benefits programme.

The numbers are among the clearest real-world signals yet that affordability — not efficacy — is now the binding constraint on GLP-1 adoption in emerging markets.

Who Is Affected

• Patients — demand keeps climbing while the benefit structure treats obesity medicines as discretionary spending rather than chronic care.
• Insurers — Discovery is expanding its HealthyWeight programme to include doctor-led assessments for anti-obesity medicines where clinically appropriate, alongside nutrition, exercise and behavioural support. A new benefit lets qualifying Group Risk members earn incentive points for meeting physical-activity goals, helping offset some of the medicine cost.
• Financing startups — Obiflex, a doctor-led weight-management company, now lets patients finance GLP-1 programmes through interest-free instalments. It expects a default rate of about 5%, carries that credit risk on its own balance sheet, runs credit checks and requires payment before further medication is dispatched. "We want to offer proper medical support, coaching and a way to pay for GLP-1s," said co-founder and CEO Shaun Barns. Novo Nordisk is financially supporting development of the buy-now, pay-later platform and a WhatsApp-based patient-support programme, without bearing the credit risk.
• Drugmakers — Aspen Pharmacare, which generated about R1.5 billion in South African sales of Eli Lilly's Mounjaro, is preparing a generic semaglutide. CEO Stephen Saad has said he expects generic GLP-1s globally to cost at least 50% less than current branded medicines. Novo Nordisk is pursuing price adjustments, lower-priced authorised copies and broader insurer coverage.

Timeline

• Three years through 2025 — GLP-1 claims at Discovery climb almost threefold to 61,200 members.
• 2025 — members claim for the medicines for just 5.4 months on average.
• October 2026 — the claims data surface publicly as insurers, drugmakers and startups roll out financing, incentive and generic-drug strategies to close the affordability gap.

What This Means for Researchers

This pattern matters well beyond South Africa. When demand for a medicine class grows threefold while covered use averages barely five months, the unmet demand goes somewhere — historically, to gray-market compounds and counterfeit pens. Every documented price barrier is a leading indicator for unverified "generic semaglutide" offers targeting price-sensitive buyers. Expect underdosed, mislabelled or entirely fake GLP-1 products to intensify in exactly those markets where cost pressure is highest — and where "cheaper" is the only claim a seller needs to make.

How to Verify Your Peptides

• How third-party lab testing works
• HPLC versus LC-MS: what each method reveals
• Identity, purity and fill-weight reports explained

Safe Alternatives

• Research-grade compounds from documented sources in the peptide directory
• Vetted suppliers in the vendor directory

Sources

Insurer claims data; industry reports; company announcements.